## Liv.52 Therapy in Cirrhosis of Liver in Children

**Vyas, K.J.,** *M.B.,B.S., D.C.H., D.Paed.*Paediatrician, Children Ward, General Hospital, Junagadh, India.

The author had previously tried the routine line of treatment on 67 cases of cirrhosis of liver in different stages in children. The results of this series acted as controls. Later on in another series of 70 cases he added Liv.52 to the routine therapy already used before.

From the 2<sup>nd</sup> series of 70 cases 20 were studied histopathologically before and after treatment.

Patients were classified as cured when after treatment, there was a total absence of any signs and symptoms of the disease and relieved when there was amelioration in signs, symptoms and reductions in the size of liver and spleen.

The author feels that though this therapy may not be a substitute for diet and other conventional therapy, the addition of Liv.52 to therapy is of very significant value in cure or relief as can be judged from the following table:

Table of Results					
	No. of cases	Cured (%)	Relieved	No Relief	Expired
Control series on routine treatment	67	1 (1%) (approx).	11 (16%)	40 (60%)	15 (23%)
Series after the addition of Liv.52 to therapy	70	15(21%)	31 (44%)	16 (23%)	8 (11%)

The author found that histopathological studies when done were very revealing. The cases that did not respond or expired showed marked fibrosis with irregular and disorganised pattern. In some there was promotion of pseudolobules and necrotic changes in the liver cells. The cases that improved with Liv.52 therapy showed prior to treatment, fibrosis with liver cell destruction and fair increase in the connective tissue but the fibrosis was not well marked. On treatment the fibrosis was less evident and in some cases the liver cells showed enlargement in size but the picture gave a distinct impression of improvement. Some of the cases showed decrease in cellular infiltration and necrotic changes and even return to almost normal liver architecture.

The author concludes that Liv.52 is a well tolerated non-toxic efficacious drug in cirrhosis of liver in children especially where it is in the early and intermediate states.